Skip to content

Andrea Miuli

14 papers in the library · 239 citations · publishing 2021-2026

Papers

Sort Most recent Most cited

Prolonged Psychological Distress Following Recreational LSD Use in a Young Adult with Multiple Vulnerability Factors: A Case Report

Clinical Neuropsychopharmacology and Addiction September 24, 2026 Giacomo D’andrea, Antonio Inserra, Andrea Miuli et al.

While psychedelic experiences are often reported as positive, adverse psychological reactions can occur. We present the case of a 19-year-old Caucasian male who presented to the ER with suicidal thoughts after taking lysergic acid diethylamide (LSD) alone. He was diagnosed with anxious state associated with panic attacks, and suicidal thoughts without ideation or behaviors. He was admitted to...

Treatment and management approaches for ketamine misuse: A systematic review of medical interventions

Journal of Substance Use and Addiction Treatment July 1, 2026 Alessio Mosca, Stefania Chiappini, Andrea Miuli et al.

INTRODUCTION: Ketamine, initially developed as an anesthetic and now increasingly prescribed for treatment-resistant depression, is also widely misused in recreational contexts. Chronic ketamine use, often leading to dependence, has been associated with severe physical complications, including ulcerative cystitis and gastrointestinal dysfunction, as well as cognitive, affective, and psychotic...

DOI: 10.1016/j.josat.2026.210061 (opens in new tab) Ketamine Psychological intervention Medline Systematic review +2

Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.

Translational Psychiatry October 31, 2025 Giacomo D’andrea, Stefania Chiappini, Laura Ciavoni et al. 3 citations

BACKGROUND: Over the past ten years, several psychedelic compounds, including tryptamines like lysergic acid diethylamide/LSD, psilocybin, ayahuasca, and dimethyltryptamine/DMT, have been tested in clinical trials for a range of psychiatric conditions, such as anxiety and depression. While these compounds are relatively available for treatment, ketamine and its S(+) enantiomer, esketamine, are...

Novel psychoactive substances (NPS) as a risk factor for psychosis: A systematic review of the literature

Neuroscience & Biobehavioral Reviews October 19, 2025 Alessio Mosca, Gianluca Mancusi, Stefania Chiappini et al. 6 citations

Novel psychoactive substances (NPS) are increasingly used by young individuals for their psychoactive effects and have been frequently associated with the emergence of psychotic symptoms and schizophrenia spectrum disorders. However, it remains unclear whether NPS use directly increases the risk of psychosis onset or whether individuals with a predisposition to psychosis are more likely to...

DOI: 10.1016/j.neubiorev.2025.106431 (opens in new tab) Psychosis Schizophrenia object-oriented programming Risk factor Synthetic cannabinoids +6

Novel perspectives for glutamatergic strategies, psychedelics and antipsychotic augmentation in Treatment Resistant Depression: A narrative review

Clinical Neuropsychopharmacology and Addiction September 25, 2025 Stefania Chiappini, Clara Cavallotto, Andrea Miuli et al. 2 citations

Introduction: Treatment-Resistant Depression (TRD) affects approximately 30–50% of patients with Major Depressive Disorder (MDD) who fail to respond to at least two adequate antidepressant trials. This condition presents substantial clinical and functional challenges, and no universally accepted treatment algorithm currently exists. Emerging therapeutic strategies, particularly glutamatergic...

Clinical Management of Synthetic-Cannabinoid-Induced Psychosis: A Systematic Review of Treatment Strategies and Outcomes.

Brain Sciences September 17, 2025 Alessio Mosca, Stefania Chiappini, Andrea Miuli et al. 1 citation

Background: Synthetic cannabinoid receptor agonists (SCRAs, commercially known as "Spice") have become a leading cause of substance-induced psychosis worldwide. These compounds show strong associations not only with acute psychotic episodes but also, in a subset of patients, with persistent or relapsing psychotic disorders, patterns that raise concern about progression to schizophrenia. Yet...

Over-the-counter Psychosis: A Systematic Review of the Misuse of Antihistamines, Cough Medicines, and Decongestants and the Risk of Developing Psychosis

Current Neuropharmacology February 20, 2025 Alessio Mosca, Stefania Chiappini, Gianluca Mancusi et al. 3 citations

BACKGROUND: The widespread availability and accessibility of over-the-counter (OTC) medicines play a vital role in modern healthcare systems, enabling individuals to manage minor health concerns independently. However, certain OTC medications possess pharmacological properties that render them susceptible to misuse and abuse, including stimulants, laxatives, sedatives, and opiate-containing...

EXPLORING VORTIOXETINE COMBINATION WITH INTRANASAL ESKETAMINE: A PROMISING ALTERNATIVE TO SSRI/SNRI - INSIGHTS FROM THE REAL-ESK STUDY

The International Journal of Neuropsychopharmacology February 1, 2025 Clara Cavallotto, Giacomo D’andrea, Andrea Miuli et al. 1 citation

Abstract Background Treatment-Resistant Depression (TRD) affects almost 30% of patients with Major Depressive Disorder (MDD) (1). Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD in combination with a Serotonin Specific Reuptake Inhibitor/SSRI or a Serotonin-Norepinephrine Reuptake Inhibitor/SNRI. There is a lack of studies investigating the effectiveness and safety of ESK-NS...

Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study.

Journal of Affective Disorders December 15, 2024 Giacomo d'Andrea, Andrea Miuli, Mauro Pettorruso et al. 6 citations

Treatment-Resistant Depression (TRD) affects almost 30 % of patients with Major Depressive Disorder (MDD). Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD in combination with a Serotonin Specific Reuptake Inhibitor/SSRI or a Serotonin-Norepinephrine Reuptake Inhibitor/SNRI. There is a lack of studies investigating the effectiveness and safety of ESK-NS in combination with...

DOI: 10.1016/j.jad.2024.09.004 (opens in new tab) Full text (opens in new tab) Esk-ns Emotional blunting Glutamate Vortioxetine +5

Piperazine Abuse and Psychosis: A Systematic Review of the Literature

Psychiatry International September 20, 2024 Alessio Mosca, Stefania Chiappini, Andrea Miuli et al. 5 citations

Background: Piperazines, synthetic compounds known for their stimulant and hallucinogenic effects, have gained prominence among novel psychoactive substances (NPS) and are frequently associated with adverse psychiatric outcomes, including psychosis. Methods: A systematic review of the literature available up to 23 May 2024 was conducted, using the PubMed, Scopus, and Web of Science databases,...

DOI: 10.3390/psychiatryint5030040 (opens in new tab) Psychosis Systematic review Piperazine Medline +1

Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: ASystematic Review of the Current Literature

Current Neuropharmacology October 20, 2022 Alessio Mosca, Stefania Chiappini, Andrea Miuli et al. 30 citations

BACKGROUND: Ibogaine and noribogaine are psychedelic substances with dissociative properties naturally occurring in plants of the Apocynaceae family. Research has shown their efficacy in treating substance use disorders (SUD), particularly in opiate detoxification, but their efficacy and toxicity are still unclear. OBJECTIVE: This review aims to assess the anti-addictive role of ibogaine and...

Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature

Brain Sciences June 27, 2021 Giovanni Martinotti, Stefania Chiappini, Mauro Pettorruso et al. 114 citations

The obsessive-compulsive spectrum refers to disorders drawn from several diagnostic categories that share core features related to obsessive-compulsive disorder (OCD), such as obsessive thoughts, compulsive behaviors and anxiety. Disorders that include these features can be grouped according to the focus of the symptoms, e.g., bodily preoccupation (i.e., eating disorders, ED) or impulse control...

DOI: 10.3390/brainsci11070856 (opens in new tab) Ketamine Eating disorders Obsessive compulsive Substance use +2

New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review.

Experimental Neurology May 1, 2021 Fabrizio Schifano, Stefania Chiappini, Andrea Miuli et al. 49 citations

The use of several new psychoactive substances (NPS) has become very popular and is posing global health risks. Chemically and pharmacologically diverse molecules are constantly emerging and are presenting with a wide range of clinical implications. Serotonin toxicity, and specifically Serotonin Syndrome (SS), might develop as a result of an over-activation of the serotoninergic system caused...

DOI: 10.1016/j.expneurol.2021.113638 (opens in new tab) Full text (opens in new tab) Bupropion New psychoactive substances Phenethylamines Serotonin syndrome +4

The Benzydamine Experience: A Systematic Review of Benzydamine Abuse

Current Neuropharmacology January 14, 2021 Stefania Chiappini, Andrea Miuli, Alessio Mosca et al. 19 citations

BACKGROUND: Both prescription and over-the-counter (OTC) drugs recently emerged among novel psychoactive substances (NPS) being reported as ingested for recreational purposes. Among them, benzydamine (BZY), normally prescribed as an OTC anti-inflammatory drug, is reportedly being diverted and recreationally used. OBJECTIVE: The aim of this study was to investigate how the misuse of BZY has been...

DOI: 10.2174/1570159x19666210113151136 (opens in new tab) Full text (opens in new tab) Recreational drug Medical prescription Adverse effect Pharmacology